Solomon BJ, Shaw A, Ignatius Ou S-H, et al. Phase 2 Study of Lorlatinib in Patients with Advanced ALK/ROS1 Non-Small-Cell Lung Cancer. 18th World Conference on Lung Cancer (WCLC) 2017, abstract OA 05.06.
Adjuvant T-DM1 bij stadium I HER2-positieve borstkanker: resultaten na 5 jaar
nov 2024 | Borstkanker